Status:
COMPLETED
Investigation of Anti-obesity Properties of Lactobacillus Sakei in Obese Human Subjects
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Obesity
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
In this study, we are going to investigate the efficacy of Lactobacillus Sakei on reduction of fat mass assessed by DEXA compared to plaebo.
Detailed Description
We are going to enroll subjects whose BMI is equal to higher than 25, and randomly assigned study material or placebo at 1:1 ratio. The treatment duration is 12 weeks.
Eligibility Criteria
Inclusion
- age 20-65 years
- BMI equal to higher than 25 kg/m2
Exclusion
- under anti-obesity medication
- uncontrolled diabetes
- uncontrolled hypertension
- any medications can influence to body weight such as thiazolidinedione, GLP-1 analogue, SGLT2 inhibitor, diuretics
- thyroid function test abnormality
- malignancy within 5 years
- immune compromised hosts or under immune suppressants
- antibiotics or probiotics withing 2 weeks
- any intervention to reduce body weight within 6 months
Key Trial Info
Start Date :
August 10 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2018
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT03248414
Start Date
August 10 2016
End Date
September 10 2018
Last Update
September 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 463-707